UGT2B28 genomic variation is associated with hepatitis B e-antigen seroconversion in response to antiviral therapy

Seroconversion of hepatitis B virus (HBV) e-antigen (HBeAg) is a critical but often-missed therapeutic goal in standard antiviral treatments. An extreme-phenotype genome-wide association study was performed, comparing untreated spontaneous recoverers (with seroconversion of HBV surface antigen) vers...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Kung-Hao, Lin, Chih-Lang, Hsu, Chao-Wei, Lai, Ming-Wei, Chien, Rong-Nan, Yeh, Chau-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036189/
https://www.ncbi.nlm.nih.gov/pubmed/27665939
http://dx.doi.org/10.1038/srep34088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036189/
https://www.ncbi.nlm.nih.gov/pubmed/27665939
http://dx.doi.org/10.1038/srep34088

Ejemplares similares